Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
167.22
-0.62 (-0.37%)
5:28:44 PM EDT: $167.06 -0.16 (-0.10%)
Products

U.S. FDA Approves Darzalex Faspro In Combination With Carfilzomib And Dexamethasone

Published: 12/01/2021 18:41 GMT
Johnson & Johnson (JNJ) - :u.s. FDA Approves Darzalex Faspro® (daratumumab and Hyaluronidase-fihj) in Combination With Carfilzomib and Dexamethasone for Patients With Multiple Myeloma After First Or Subsequent Relapse.
Janssen - Approval of Darzalex Faspro Follows Regulatory Submission to FDA in February 2021.